Ticker

Enlivex Therapeutics (NASDAQ: ENLV) executives used the company's fourth-quarter and full-year 2025 earnings call to outline what they described as a "dual-engine" strategy that combines clinical-stage drug development with a digital-asset treasury focused on decentralized prediction markets. Executive Chairman Shai Novik and CEO Oren Hershkovitz said 2025 marked a "defining and transformational year," highlighted…

According to the Rain Foundation, anyone using OpenClaw or other AI agents can generate a live prediction market via a single prompt to the agent, without manual coding or centralized gatekeepers      The Rain Foundation announced a $5 million grant program to support developers and creators worldwide in building, launching, and monetizing their own independent prediction markets via the Rain decentralized platform…

Earnings Driven by Treasury and Treasury-Related Asset Appreciation Nes-Ziona, Israel, March 25, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV; “Enlivex” or “the Company”) today reported financial results and business highlights for the year ended December 31, 2025.

$21 Million debt financing, convertible to ENLV ordinary shares at fixed $2.69175 per share, a 264% premium to the Nasdaq closing price on March 20, 2026, with a single institutional investor The Company exercised an option to acquire additional 3,030,303,030 RAIN tokens at $0.0033 per token, a 62% discount to its closing price on March 22, 2026, for a total aggregate purchase amount of $10 million The Company and…

Enlivex's first regulatory approval for a late-stage global Phase 2b study in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis following the implementation of its dual-engine value creation model:  A clinical-stage quality longevity program powered by a prediction markets treasury strategy.  IND clearance follows the positive 3 and 6-month data readout from the Company's Phase 1/2a multicenter, randomized,…